Manchester, England-based Phagenesis is now planning a targeted launch in the U.S.
The company designed the first-of-its-kind therapy to use pharyngeal electrical stimulation (PES). It aims to restore swallowing control in patients with severe dysphagia post-stroke. The FDA granted Phagenyx breakthrough device designation in January 2020. It is also available in Europe.
“Dysphagia affects millions of people worldwide, and many do not receive the desired outcome with currently available treatments. Adding an innovative therapy like Phagenyx has the potential to accelerate results and may allow the patient to spend fewer days in the hospital, which would significantly improve quality of care and patient experience,” said Marta Kazandjian, department head for speech-language pathology and swal…